Sam Altman's Psychedelic Breakthrough: How The OpenAI Visionary Plans To Transform Mental Health Care With MDMA

Sam Altman, co-founder of OpenAI and the visionary behind ChatGPT, recently opened up about his transformative experiences with psychedelics in his appearance on the podcast Life in Seven Songs. The tech executive shared personal anecdotes about how psychedelic experiences profoundly impacted his mental health, helping him overcome anxiety and find happiness.

Altman told to host Sophie Bearman that he once considered himself a “very anxious, unhappy person,” but psychedelic experiences—particularly a retreat in Mexico—changed his life significantly. “Doing psychedelics was one of the most transformative experiences of my life,” he said, noting that the experience helped him become a “calm person” and allowed him to focus more effectively on his work.

While Altman did not specify which psychedelics he used, he did mention that the Mexico retreat was particularly significant. “If you had told me that, like, one weekend-long retreat in Mexico was going to significantly change that, I would have said absolutely not. And it really did,” Altman remarked, highlighting the unexpected impact the experience had on his mental state.

Altman's Vision For Safe And Effective Psychedelic Therapy: Journey Colab

Altman is now setting his sights on transforming mental health care with psychedelic drugs. According to Business Insider, as chairman of the start-up Journey Colab, he is investing in the potential of psychedelics such as MDMA and psilocybin to treat mental health conditions like depression, PTSD and drug addiction.

Journey Colab, led by CEO Jeeshan Chowdhury, aims to guide these powerful substances through the final stages of clinical trials and develop a safe, effective model for administering them. Their approach is to work with luxury rehab centers like All Points North to ensure that psychedelic treatments are offered in controlled, high-support environments. 

Altman says his interest in psychedelics stems from their unrealized potential. Reflecting on early MDMA studies, he said, “I remember looking at it thinking, like, ‘That can't be real, it's too good.'” Despite the uncertainty around how psychedelic medicine will evolve economically, Altman hopes Journey Colab's approach will shape a model that is both effective and safe.

Chowdhury envisions Journey Colab as a specialty service that provides psychedelic care at rehab centers, akin to how hospitals contract wound-care specialists. Initially, Journey plans to partner with firms conducting clinical trials on MDMA and psilocybin, utilizing the All Points North rehab center near Vail, Colorado as a testing ground.

All Points North, known for its luxury services and veteran care contracts, provides the high-end environment Journey needs to develop its treatment model. However, Journey Colab also aims to make psychedelic therapy accessible to marginalized communities, reserving 10% of its founding equity for a trust benefiting U.S. Indigenous groups.

Chowdhury likens Journey's strategy to Tesla's TSLA: "We're building the Tesla Roadster to try and get to the Model 3." While the focus is currently on luxury rehab environments, the long-term goal is to make these therapies more widely available.

Image credits – Shutterstock